Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4793030
Max Phase: Preclinical
Molecular Formula: C31H36ClNO2
Molecular Weight: 453.63
Molecule Type: Unknown
Associated Items:
ID: ALA4793030
Max Phase: Preclinical
Molecular Formula: C31H36ClNO2
Molecular Weight: 453.63
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)N1CC=C(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(O)c3)cc2)CC1.Cl
Standard InChI: InChI=1S/C31H35NO2.ClH/c1-23(2)32-19-17-25(18-20-32)24-13-15-27(16-14-24)31(28-10-6-11-29(34)22-28)30(12-7-21-33)26-8-4-3-5-9-26;/h3-6,8-11,13-17,22-23,33-34H,7,12,18-21H2,1-2H3;1H/b31-30+;
Standard InChI Key: BDFBNGKZRQQCQN-FJISBNMDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 453.63 | Molecular Weight (Monoisotopic): 453.2668 | AlogP: 6.62 | #Rotatable Bonds: 8 |
Polar Surface Area: 43.70 | Molecular Species: BASE | HBA: 3 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 9.50 | CX Basic pKa: 8.85 | CX LogP: 5.87 | CX LogD: 4.71 |
Aromatic Rings: 3 | Heavy Atoms: 34 | QED Weighted: 0.38 | Np Likeness Score: 0.08 |
1. Kim J,Hwang H,Yoon H,Lee JE,Oh JM,An H,Ji HD,Lee S,Cha E,Ma MJ,Kim DS,Lee SJ,Kadayat TM,Song J,Lee SW,Jeon JH,Park KG,Lee IK,Jeon YH,Chin J,Cho SJ. (2020) An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer., 205 [PMID:32758860] [10.1016/j.ejmech.2020.112501] |
Source(1):